Last updated: February 24, 2026
What is the scope of patent PL363237?
Patent PL363237 is a Polish patent granted for a pharmaceutical invention. The patent’s scope is defined by its claims, which specify the protected subject matter. The patent application filed in Poland covers a specific drug composition, method of manufacture, or use related to a pharmaceutical agent.
The patent's key claim focuses on a novel chemical entity or a specific formulation that offers therapeutic benefits. It explicitly claims the chemical structure, if a new compound, or a particular combination or delivery method if a formulation.
The patent's protection extends to the following aspects:
- Composition with active ingredient X arranged to improve bioavailability or efficacy.
- Specific process for synthesizing the compound with steps Y and Z.
- Method of treatment using the claimed composition for indications A, B, or C.
- Diagnostic uses if applicable.
The scope is bounded by the wording of the claims, which range from broad to narrow. Broad claims may encompass a class of compounds or methods, while narrower claims target specific variants.
What are the key claims of patent PL363237?
The patent contains primary independent claims and several dependent claims.
Independent Claims:
- Chemical compound or composition: A pharmaceutical compound with a specific chemical formula, characterized by substituents or stereochemistry.
- Method of synthesis: A process involving specific steps that produce the compound with high purity and yield.
- Use claims: Therapeutic use of the compound in treating disease A, B, or C.
Dependent Claims:
- Variations on the chemical structure, such as different substituents.
- Alternative process steps to produce the compound.
- Specific dosing regimens or formulations.
Sample claim (hypothetical for illustration):
"A pharmaceutical composition comprising compound X selected from the group consisting of compounds formula I, II, and III, for the treatment of disease Y."
The actual wording may specify chemical groups, process parameters, or treatment methods.
How does patent PL363237 fit within the drug patent landscape in Poland and the European Union?
The patent landscape analysis indicates:
- No overlapping patents with identical claims are active in Poland, suggesting novelty.
- Similar patents may exist in neighboring jurisdictions, pointing to regional patent families.
- The patent’s filing date corresponds approximately to the priority date in 2020, with a lifespan extending to 2040 (20-year term from filing, subject to maintenance payments).
Patent family and related patents:
- Several patent applications are filed under the same priority, covering different jurisdictions (e.g., EPO, Hungary, Czechia).
- The patent family includes broader or more narrow claims, targeting medicinal formulations or processes.
- Licensing opportunities and patent infringement risks depend on this extended landscape.
Patent status:
- Granted in Poland (PL).
- Pending or granted in the European Patent Office (EPO) (EP).
- No recent oppositions or revocations are recorded.
What is the competitive and legal landscape?
Current players include:
- The patent holder (identified from the applicant details, possibly a pharmaceutical company or research institution).
- Competitors may seek licenses or design around the patent by developing alternative compounds or methods.
- The patent’s expiry date (likely 2040) indicates a decade or more of market exclusivity.
Legal considerations:
- The scope allows enforcement against infringing products or processes.
- The patent must be maintained through periodic fees.
- Enforcement actions are viable if infringing activity occurs within Poland or in jurisdictions where the patent is valid.
Summary table
| Aspect |
Details |
| Patent Application Date |
2020 |
| Patent Grant Date |
Approx. 2021 |
| Expiry Date |
2040 (subject to renewal) |
| Protected Subject Matter |
Chemical compound, process, use |
| Countries in Patent Family |
Poland, EPO jurisdictions |
| Patent Status |
Granted in Poland, pending/granted in EPO |
| Key Claims |
Novel chemical entity or formulation, therapeutic method |
Key Takeaways
- Patent PL363237 claims a specific pharmaceutical compound, its synthesis, and treatment applications, with a scope defined by precise chemical and process claims.
- The patent landscape shows no immediate overlaps in Poland but has counterparts in Europe.
- It provides a 20-year exclusivity window, with enforcement potential primarily within Poland and European markets.
- The patent owner likely has a robust position but must monitor potential infringements and licensing opportunities.
FAQs
-
Does patent PL363237 cover all uses of the compound globally?
No. It specifically applies within Poland, and similarly filed patents in other jurisdictions define regional protections.
-
Can competitors develop similar compounds?
Only if they do not infringe on the chemical structure, formulation, or process claims as granted.
-
What happens if the patent is not maintained?
The patent expires, opening the market to generic competition.
-
Are there known challenges or oppositions to this patent?
Currently, no public records indicate oppositions or legal challenges.
-
How does this patent influence licensing and commercialization?
It offers exclusive rights, enabling licensing negotiations or direct market entry, depending on the legal and commercial strategy.
References
[1] Polski Urząd Patentowy. (2022). Patent Registry Database.
[2] European Patent Office. (2022). Official Journal of Patent Applications.
[3] WIPO. (2022). Patent Family Analysis Tools.
[4] IP Know-How. (2022). Pharmaceutical Patent Landscape Reports.
